Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma

Inclusion criteria Clin A * Age ≥18 \< or =60 years (patients older than 60 years are excluded because of the intensive chemotherapy and transplant procedures) * Histologically proven diagnosis of PTCL, including the following categories: PTCL-U (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma),intestinal T - NHL * Advanced stage disease (stage II-IV) or stage I and aaIPI score ≥ 2 * Written informed consent Inclusion criteria Clin B * Age \>60 and ≤75 years (patients older than 75 years are excluded because of the intensive chemo-immunotherapy program) * Histological proven diagnosis of PTCL, including the following categories: PTCL-U (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma), intestinal T - NHL * Advanced-stage disease (stage II-IV) or stage I and aaIPI score ≥ 2 * Informed written consent In clinical study A (Clin A) we are planning to evaluate the efficacy and the feasibility of an intensified chemo-immunotherapy program including auto-SCT or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and \< or = 60 years. In clinical study B (Clin B) we intend to verify the efficacy and the feasibility of a combined immuno-chemotherapy approach in a subset of elderly pts aged \> 60 and \< or = 75 years.